Executive Director
Gilead Sciences, Inc.
More than 20 years of drug development experience, obtained at three international pharma/biopharma companies, encompassing research in transporter-related ADME-PK-Tox; He is an Experienced department leader in developing scientific-strategic plans to translate ADME-PK/PD from pre-clinical to human; Highly proficient at leveraging non-clinical data and information combined with PK/PD and PBPK modeling & simulation approaches to anticipate and predict properties in human. He is dedicated to discovering and developing new medicines for patients across multiple therapeutic areas, including oncology, inflammation, cardiovascular, anti-infectives, and metabolic liver diseases; Dr. Lai is an associate editor/editorial board member of top-ranking DMPK journals: DMD, BDD, JPS, Frontier Pharmacology, etc. The author of a book, book chapters, and over 180 original publications.